Company news

Natera, Inc. news in 2022

Natera, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Natera Supports Updated ISHLT Guidelines for the Care of Heart Transplant Patients

December 20, 2022

Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers

December 8, 2022

Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer Symposium

December 6, 2022

Natera Announces Publication of Clinical Experience Study with 18,984 Twin Pregnancies Supporting Excellent Performance of Panorama™ NIPT

December 5, 2022

Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 22, 2022

New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients

November 20, 2022

Natera Announces Pricing of Follow-On Offering

November 14, 2022

Natera Reports Third Quarter 2022 Financial Results

November 7, 2022

Natera Awarded National MRD Testing Contract by the U.S. Department of Veterans Affairs

November 1, 2022

Natera to Report its Third Quarter 2022 Results on November 8th

October 31, 2022

Natera to Participate in Credit Suisse 31st Annual Healthcare Conference

October 31, 2022

New Publication Validates Performance of Natera's Signatera™ MRD Test in Ovarian Cancer

October 5, 2022

Trifecta Study Demonstrates Prospera™ Kidney dd-cfDNA Test Outperforms DSA in Predicting Antibody Mediated Rejection

October 3, 2022

Natera Announces 2025 ESG Goals with Publication of 2021 Report

September 28, 2022

Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings

September 11, 2022

Natera Earns Great Place to Work Certification™ for Second Consecutive Year

August 24, 2022

Natera Announces Enrollment Completion for RenaCARE Study

August 10, 2022

Natera Announces Q-Sub Filing with FDA for its Panorama® NIPT

August 9, 2022

Natera Reports Second Quarter 2022 Financial Results

August 3, 2022

Natera Announces Second Quarter 2022 Earnings Conference Call

July 31, 2022

Trifecta Study Establishes New Validation Standard for dd-cfDNA in Kidney Transplant Rejection With Largest Prospective, Multisite, Fully Biopsy-Matched Study

June 28, 2022

Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology

May 23, 2022

Natera Reports First Quarter 2022 Financial Results

May 4, 2022

Natera Announces First Quarter 2022 Earnings Conference Call

May 1, 2022

Natera Announces Definitive Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease (CKD)

April 25, 2022

Natera Adds to Organ Health Medical Affairs Leadership Team

April 5, 2022

Natera Announces Updated Signatera™ MRD Data from CIRCULATE-Japan Presented in Plenary Talk at the Society of Surgical Oncology Conference, and Activation of CIRCULATE-US Trial

March 20, 2022

Natera Achieves Milestone of Enrolling First 1,000 Patients in its BESPOKE CRC Study

March 10, 2022

Natera Reports Fourth Quarter and Full Year 2021 Financial Results

February 23, 2022

Natera Announces Fourth Quarter and Fiscal 2021 Earnings Conference Call

February 16, 2022

Natera to Present Latest Signatera™ MRD Data in Colorectal and Pancreatic Cancers at the ASCO GI Symposium 2022, and Host Special Investor Call

January 18, 2022

Natera Announces Expansion Into Early Cancer Detection and Screening

January 5, 2022

Calls in 2022

Decks in 2022